STING Agonist IMSA101 clinical trials
Also written IMSA101.
How each study uses STING Agonist IMSA101 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the STING Agonist IMSA101 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- IMSA101
- 5
Studies by the year they started
5 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2023 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
ImmuneSensor Therapeutics Inc. (4) · University of Texas Southwestern Medical Center (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test STING Agonist IMSA101.
- Oct 2027Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney CancerPhase 2 · University of Texas Southwestern Medical Center
Studies
Open first, then newest update. How each study uses STING Agonist IMSA101 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney CancerRecruitingPhase 2University of Texas Southwestern Medical CenterNCT06601296Written as IMSA101How we know
- Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor MalignanciesTerminatedPhase 2ImmuneSensor Therapeutics Inc.NCT05846659Written as IMSA101How we know
- Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCCTerminatedPhase 2ImmuneSensor Therapeutics Inc.NCT05846646Written as IMSA101How we know
- Safety and Efficacy Study of IMSA101 in Refractory MalignanciesCompletedPhase 1/2ImmuneSensor Therapeutics Inc.NCT04020185Written as IMSA101How we know
- A Rollover Study for Subjects Who Completed Participation in IMSA101-101 TrialActive, not recruitingPhase 1ImmuneSensor Therapeutics Inc.NCT06026254Written as IMSA101How we know